Tregzi is the second cell therapy to be approved by the FDA for use in the context of managing GVHD in HSCT patients, albeit ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

Women with polyendocrine metabolic ovarian syndrome (PMOS) in the UK should get diagnosed sooner and be offered an annual review of their condition, according to new guidance from NICE. Draft guidance ...

Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder (SAD), cratering ...

The Memo deal falls into the latter camp, as while the BK polyomavirus is common, it usually remains inactive in the body and only causes problems in people with a weakened immune system, including ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

French pharma company Ipsen has agreed to buy cancer biotech Kartos Therapeutics of the US for $450 million upfront, gaining ...

Members of the China Select Committee in the US House have launched a national security investigation into a number of big pharma companies, asking for details of their use of clinical trial sites in ...

In a second M&A announcement today, Zymeworks has reached an agreement to buy Theravance Biopharma, claiming rights to ...

Viridian Therapeutics has fired a shot across Amgen's bows with FDA approval of Lumvoa, the first direct rival to Amgen's ...

Eli Lilly, Regeneron, and five other companies have been selected to take part in the FDA's PreCheck pilot programme, designed to make it easier and quicker to set up US manufacturing facilities. The ...